Use of high flow nasal cannula oxygen therapy for patients infected with SARS-CoV-2 outside intensive care setting
Description
CONCLUSIONS: Use of HFNC outside ICU setting showed benefit to patients suffering from COVID-19 related acute hypoxemic respiratory failure (AHRF). Serial SF ratio monitoring at 48 and 72 hours after therapy initiation might serve as predictors of
